EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases

Sarah A Weiss iD, Dijana Djureinovic iD, Wei Wei, Thuy Tran, Matthew Austin, Joseph Markowitz iD, Zeynep Eroglu iD, Nikhil I Khushalani iD, Upendra Hegde iD, Justine Cohen iD, Mario Sznol iD, Gail Anderson und 9 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-02219 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Sarah A Weiss und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Brain Neoplasms, Melanoma, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Anti–vascular endothelial growth factor therapy enhances PD-1 inhibitor activity in preclinical models and has been used to treat perilesional cerebral edema and radiation necrosis. METHODS We conducted a two-institution phase II trial of bevacizumab and pembrolizumab in patients with untreated melanoma brain metastasis (MBM) (ClinicalTrials.gov identifier: NCT02681549 ). Patients were anti–PD-(L)-1–naïve, and had ≥one asymptomatic, nonhemorrhagic 5-20 mm MBM, not requiring immediate local therapy or steroids. RESULTS Thirty-seven patients received four doses of bevacizumab and pembrolizumab every 3 weeks followed by up to 2 years of pembrolizumab. The brain metastasis response rate (primary end point) was 54.1% (95% CI, 36.9 to 70.5). The extracranial response rate was 56.3% (95% CI, 37.7 to 73.6). Median intracranial progression-free survival was 2.2 years (95% CI, 0.41 to not reached [NR]). Median overall survival (OS) was 4.3 years (95% CI, 1.6 to NR). Four-year OS rate was 51.6%. Grade 3 treatment-related adverse event rates from bevacizumab and pembrolizumab were 10.8% and 18.9%, respectively. Higher pretreatment vessel density in metastatic tumors and smaller on-therapy increases in circulating angiopoietin-2 were associated with response. CONCLUSION Pembrolizumab with bevacizumab was well tolerated and demonstrated substantial activity in patients with untreated MBM with promising OS, justifying further evaluation of this regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedBrain NeoplasmsMelanomaAntineoplastic Combined Chemotherapy ProtocolsSkin NeoplasmsHumansBevacizumabMaleFemaleMiddle AgedAgedAdultAged, 80 and overProgression-Free Survival

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedBevacizumab

Autor:innen und Institutionen

  • Medical Oncology, Rutgers Cancer Institute, New Brunswick, NJ.
  • Medical Oncology, Yale University School of Medicine, New Haven, CT.
  • Biostatistics, Yale University School of Medicine, New Haven, CT.
  • Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL.
  • Medical Oncology, University of Connecticut School of Medicine, Farmington, CT.
  • Medical Oncology, Dana Farber Cancer Institute, Boston, MA.

ORCID-Profile: Sarah A Weiss, Dijana Djureinovic, Joseph Markowitz, Zeynep Eroglu, Nikhil I Khushalani, Upendra Hegde, Justine Cohen, Mario Sznol, Amit Mahajan, Sarah Goldberg, Veronica Chiang, Harriet M Kluger

Förderung

  • NCI NIH HHS

Zitieren

APA

Weiss, S. A., Djureinovic, D., Wei, W., Tran, T., Austin, M., Markowitz, J., Eroglu, Z., Khushalani, N. I., Hegde, U., Cohen, J., Sznol, M., Anderson, G., Johnson, B., Piteo, C., Mahajan, A., Adeniran, A., Jilaveanu, L., Goldberg, S., Chiang, V., …, & Kluger, H. M. (2025). Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02219

Vancouver

Weiss SA, Djureinovic D, Wei W, Tran T, Austin M, Markowitz J, et al. Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-02219

BibTeX
@article{Weiss2025,
  author = {Weiss, Sarah A and Djureinovic, Dijana and Wei, Wei and Tran, Thuy and Austin, Matthew and Markowitz, Joseph and Eroglu, Zeynep and Khushalani, Nikhil I and Hegde, Upendra and Cohen, Justine and Sznol, Mario and Anderson, Gail and Johnson, Barbara and Piteo, Cecily and Mahajan, Amit and Adeniran, Adebowale and Jilaveanu, Lucia and Goldberg, Sarah and Chiang, Veronica and Forsyth, Peter and Kluger, Harriet M},
  title = {Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-02219}
}
Kostenlos starten →